v3.25.1
Note 8 - Accrued Liabilities
12 Months Ended
Jun. 30, 2025
Notes to Financial Statements  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Note 8 - Accrued liabilities

 

Accrued liabilities consist of the following:

 

 

June 30,

 

 

2024

  

2023

 

 

(in thousands)

 

Accrued savings offers

 $11,054  $15,739 

Accrued program liabilities

  9,964   11,012 

Accrued customer and product related fees

  5,395   6,579 

Accrued compensation

  4,603   5,299 

Return reserve

  4,832   5,683 

Other accrued liabilities

  2,295   1,650 

Total accrued liabilities

 $38,143  $45,962 

 

Accrued savings offers represent programs for the Company’s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. Accrued program liabilities include government and commercial rebates. Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions such as royalties for Pediatric Portfolio products, accrued distributor fees, and Medicaid liabilities. Accrued employee compensation includes sales commissions, paid time off earned, accrued payroll and accrued bonus. The return reserve represents the Company’s accrual for estimated product returns. Other accrued liabilities consist of various other accruals, none of which individually or in the aggregate represent greater than five percent of total liabilities.

 

The following table details the change in return reserve for the periods presented:

 

 

Return Reserve

 

 

(in thousands)

 

Balance, June 30, 2022

 $5,559 

Reduction of net revenue

  6,785 

Payments

  (6,661)

Balance, June 30, 2023

  5,683 

Reduction of net revenue

  5,838 

Payments

  (6,689)

Balance, June 30, 2024

 $4,832